Revolutionizing Drug Development Approaches
Kenox Pharmaceuticals Inc, a leading name in the development of innovative Orally Inhaled and Nasal Drug Products (OINDPs), has recently announced an exciting extension of its capabilities. The introduction of small scale non-sterile GMP capabilities marks a significant enhancement to its already comprehensive drug development services. This strategic move is all about supporting GLP pre-clinical studies and reflects Kenox's dedication to providing a fast-tracked journey from molecule development to clinical readiness. Kenox's commitment allows them to equip partners with the necessary tools and expertise, ultimately bringing transformative therapies to market more quickly.
New Capabilities in Drug Development
The new capabilities encompass a clean room designed for compounding, the fill-finish process, and the release of non-sterile nasal sprays and dry powders. Additionally, Kenox Pharmaceuticals is focused on further expanding these capabilities to enable GMP batch manufacturing for both non-sterile and sterile OINDPs during the early phases of clinical trials, including Phase I and II. This comprehensive suite of capabilities is designed to simplify and mitigate risks associated with the initial stages of drug development, providing a seamless service experience for clients.
Quotes from Leadership
“I am thrilled about this timely expansion,” expressed Sitaram Velaga, Founder, President, and CEO of Kenox Pharmaceuticals Inc. “It reflects our unwavering dedication to supporting our partners in their quest to develop groundbreaking therapeutics addressing unmet medical needs, all while keeping quality and efficiency at the forefront.” This leadership insight emphasizes Kenox’s commitment to excellence and collaboration with various stakeholders including a talented internal team and supportive partners.
Targeted Therapeutic Areas and Innovative Solutions
With the newly launched capabilities, Kenox Pharmaceuticals Inc is well-equipped to cater to a variety of OINDP dosage forms that target multiple therapeutic areas. This includes but is not limited to specialties such as cardiology, psychiatry, antimicrobial/antiviral treatment, pain management, and addressing rare diseases. Kenox's complete understanding of formulation design, pre-clinical and clinical manufacturing, and regulatory support enables them to present a high-quality end-to-end solution tailored for biopharmaceutical innovators. Their unique flexibility and scalability also provide the capability to serve a diverse clientele, from startups to established pharmaceutical giants.
About Kenox Pharmaceuticals
Founded in 2018 and located in the Princeton area, Kenox Pharmaceuticals specializes in the development of pharmaceutical aerosol products. Their expertise includes soft mist inhalers (SMIs), pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs), nebulizers, nasal sprays, and ophthalmic products. As a dedicated contract development organization, Kenox brings extensive knowledge in formulation design, compounding, fill-finish processes, and compliance with stringent testing standards.
Contacting Kenox Pharmaceuticals
If you're interested in connecting with Kenox for business inquiries or media relations, their contact information is available. Their team is eager to assist clients and partners in navigating the complexities of drug development effectively. Reach out to Kenox for comprehensive insights and support in your therapeutic pursuits.
Frequently Asked Questions
What new capabilities has Kenox Pharmaceuticals added?
Kenox Pharmaceuticals has introduced small scale non-sterile GMP capabilities to support GLP pre-clinical studies as part of their drug development services.
Which therapeutic areas does Kenox Pharmaceuticals focus on?
Kenox focuses on various therapeutic areas, including cardiology, psychiatry, antimicrobial/antiviral treatments, pain management, and rare diseases.
How does Kenox support OINDP development?
Kenox supports OINDP development by providing a complete suite of services from formulation design to clinical manufacturing and regulatory support.
What is the vision of Kenox Pharmaceuticals in drug development?
Kenox aims to accelerate the journey from molecule to clinic, ensuring quality and efficiency in bringing innovative therapies to market.
When was Kenox Pharmaceuticals established?
Kenox Pharmaceuticals was established in 2018 and is based in the greater Princeton area.
